Founded Year

2019

Stage

Series B | Alive

Total Raised

$321M

Valuation

$0000 

Last Raised

$221M | 3 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+96 points in the past 30 days

About Orna Therapeutics

Orna Therapeutics is a biotechnology company involved in the development of circular RNA therapeutics and lipid nanoparticle (LNP) delivery systems. The company's offerings include engineered circular RNA (oRNA) medicines meant to treat various diseases and LNP technologies that deliver these RNA therapies to targeted sites in the body. Orna Therapeutics serves sectors related to oncology, autoimmune disease treatment, and genetic disorders. It was founded in 2019 and is based in Cambridge, Massachusetts.

Headquarters Location

620 Memorial Drive 2nd Floor

Cambridge, Massachusetts, 02139,

United States

Loading...

Loading...

Expert Collections containing Orna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Orna Therapeutics is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,276 items

Orna Therapeutics Patents

Orna Therapeutics has filed 17 patents.

The 3 most popular patent topics include:

  • molecular biology
  • rna
  • biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/3/2023

12/31/2024

Molecular biology, RNA, Biotechnology, Gene expression, Genetics

Grant

Application Date

11/3/2023

Grant Date

12/31/2024

Title

Related Topics

Molecular biology, RNA, Biotechnology, Gene expression, Genetics

Status

Grant

Latest Orna Therapeutics News

米Orna社、環状RNAの抗CD19 in vivo CAR療法が自己免疫疾患前臨床モデルで効果

Jun 4, 2025

米Orna Therapeutics(オルナ・セラピューティクス)社は2025年5月15日、米遺伝子細胞治療学会(ASGCT)で、他家抗CD19 in vivoキメラ抗原受容体(CAR)療法(CD19 in vivo CAR)の最新データを発表した。同社が保有する環状RNAの基盤技術「oRNA」と脂質ナノ粒子(LNP)を用いた免疫システムへの送達技術「panCAR」により創出されたCD19 in vivo CARが、自己免疫疾患を適応候補として実施した前臨床試験で、ヒト化マウスモデル、非ヒト霊長類(NHP)モデルに強力かつ持続的なB細胞除去効果を示した。同社は2026年の臨床入りを目指すとしている。

Orna Therapeutics Frequently Asked Questions (FAQ)

  • When was Orna Therapeutics founded?

    Orna Therapeutics was founded in 2019.

  • Where is Orna Therapeutics's headquarters?

    Orna Therapeutics's headquarters is located at 620 Memorial Drive, Cambridge.

  • What is Orna Therapeutics's latest funding round?

    Orna Therapeutics's latest funding round is Series B.

  • How much did Orna Therapeutics raise?

    Orna Therapeutics raised a total of $321M.

  • Who are the investors of Orna Therapeutics?

    Investors of Orna Therapeutics include Merck & Co, MPM BioImpact, F2 Ventures, Kite Pharma, Pagsgroup and 6 more.

  • Who are Orna Therapeutics's competitors?

    Competitors of Orna Therapeutics include Harness Therapeutics, Laronde, VaxEquity, Strand Therapeutics, Translate Bio and 7 more.

Loading...

Compare Orna Therapeutics to Competitors

Strand Therapeutics Logo
Strand Therapeutics

Strand Therapeutics focuses on the development of programmable, long-acting mRNA therapeutics within the biotechnology sector. The company offers a platform for creating mRNA drugs that are designed to deliver precise, multi-functional, and potentially curative treatments by programming logic-based circuits into mRNA to control protein expression in targeted cells. Strand Therapeutics' products are primarily aimed at improving treatment options for cancer and other life-threatening diseases. It was founded in 2017 and is based in Boston, Massachusetts.

V
VaxEquity

VaxEquity develops RNA-based therapeutics and vaccines designed to meet medical needs. It specializes in amplifying the impact of RNA vaccines and therapeutics by using its self-amplifying RNA platform and provides better protein expression. The company was founded in 2020 and is based in Cambridge, U.K.

H
Harness Therapeutics

Harness Therapeutics operates as a biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases. The company specializes in messenger ribonucleic acid (mRNA)-targeted oligonucleotide-based methodologies to increase protein levels in a controlled manner. It aims to transform the treatment of conditions such as Alzheimer's, Parkinson's, and Huntington's disease. Harness Therapeutics primarily serves the healthcare sector. It was formerly known as Transine Therapeutics. Harness Therapeutics was founded in 2018 and is based in Cambridge, United Kingdom.

Sapreme Technologies Logo
Sapreme Technologies

Sapreme Technologies is a preclinical-stage biotech company focused on developing RNA therapeutics for genetically driven diseases. The company's main offerings include endosomal escape technology that facilitates the delivery of large molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to intracellular targets in various tissues, including the liver, muscle, heart, kidney, and brain. Sapreme's technology platform aims to improve receptor-targeted delivery and endosomal release of therapeutics in conditions like neuromuscular, renal, and cardiometabolic diseases. It was founded in 2016 and is based in Utrecht, Netherlands.

C
Cook MyoSite

Cook MyoSite focuses on muscle cell technology and regenerative medicine. The company provides primary human skeletal muscle cells and laboratory research services, including custom manufacturing and analysis for research purposes. Cook MyoSite serves the medical research and clinical development sectors. It was founded in 2002 and is based in Pittsburgh, Pennsylvania.

Versameb Logo
Versameb

Versameb is a biotechnology company that focuses on the discovery and development of RNA-based drugs. The company provides solutions for modulating protein expression and influencing therapeutic targets using a molecular construct. Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts to expand the use of RNA therapeutics. It was founded in 2017 and is based in Basel, Switzerland.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.